In a recent study, researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers. Funded by ICRF (Israel Cancer Research Fund), the results of the study, were published in November 2020 in Science Advances.
The researchers developed a novel lipid nanoparticle-based delivery system that specifically targets cancer cells and destroys them by genetic manipulation. The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as molecular scissors that cut the cells’ DNA. The research is based on the Nobel Prize in Chemistry 2020 winning method of genome editing developed by Emmanuelle Charpentier, Max Planck Unit for the Science of Pathogens, Berlin and Jennifer A. Doudna, University of California, Berkeley, USA.
The study was conducted in the laboratory of Prof Dan Peer, Head, Laboratory of Precision Nanomedicine at the Shmunis School of Biomedicine and Cancer Research, TAU. The research was conducted by Dr Daniel Rosenblum together with Ph.D. student Anna Gutkin and colleagues at Prof. Peer’s laboratory, in collaboration with Dr Dinorah Friedmann-Morvinski from the School of Neurobiology, Biochemistry & Biophysics at TAU; Dr Zvi R Cohen, Director of the Neurosurgical Oncology Unit and Vice-Chair of the Department of Neurosurgery at the Sheba Medical Center; Dr Mark A Behlke, Chief Scientific Officer at IDT Inc. and his team; and Prof Judy Lieberman of Boston Children’s Hospital and Harvard Medical School.
“This is the first study in the world to prove that the CRISPR genome editing system can be used to treat cancer effectively in a living animal,” said Prof Peer. “It must be emphasised that this is not chemotherapy. There are no side effects, and a cancer cell treated in this way will never become active again. The molecular scissors of Cas9 cut the cancer cell’s DNA, thereby neutralizing it and permanently preventing replication.”
To examine the feasibility of using the technology to treat cancer, Prof Peer and his team chose two of the deadliest cancers: glioblastoma and metastatic ovarian cancer. Treatment with CRISPR-LNPs in a metastatic ovarian cancer mice model increased their overall survival rate by 80 per cent.
“The CRISPR genome editing technology, capable of identifying and altering any genetic segment, has revolutionised our ability to disrupt, repair or even replace genes in a personalised manner. Despite its extensive use in research, clinical implementation is still in its infancy because an effective delivery system is needed to safely and accurately deliver the CRISPR to its target cells. The delivery system we developed targets the DNA responsible for the cancer cells’ survival. This is an innovative treatment for aggressive cancers that have no effective treatments today,” said Prof Peer.
The researchers noted that by demonstrating its potential in treating two aggressive cancers, the technology opens numerous new possibilities for treating other types of cancer as well as rare genetic diseases and chronic viral diseases such as AIDS.
“We now intend to go on to experiments with blood cancers that are very interesting genetically, as well as genetic diseases such as Duchenne muscular dystrophy. It will probably take some time before the new treatment can be used in humans, but we are optimistic. The whole scene of molecular drugs that utilize messenger RNA (genetic messengers) is thriving – in fact, most COVID-19 vaccines currently under development are based on this principle. When we first spoke of treatments with mRNA twelve years ago, people thought it was science fiction. I believe that in the near future, we will see many personalised treatments based on genetic messengers – for both cancer and genetic diseases. Through Ramot, the Technology Transfer Company of TAU, we are already negotiating with international corporations and foundations, aiming to bring the benefits of genetic editing to human patients,” informs Prof Peer.
(All Rights Reserved)